The Vaccine Program’s Intended or Unintended Consequences? A Tale of Two Hepatitis B Studies and Genocide
Foreword by
Leonard G. Horowitz, DMD, MA, MPH, DNM (hon.), DMM (hon.)
Kudos to Robert F. Kennedy, Jr. for this effort to bring greater awareness to hepatitis B (HepB) vaccine risks and falsely promoted benefits. Unfortunately, in my opinion and experience, this intelligence not only comes decades late, but its future is dim. By favoring “safer vaccines,” and ceding to political pressures and psycho-social memes that accept the antiquated and barbaric notion of intoxication for “immunization” and “herd immunity,” attorney Kennedy has vicariously aided-and-abetted by willful blindness ongoing genocide.
A decade ago I communicated with United Nations officials about the international AIDS COMMUNITY members who worked to censor my peer reviewed scientific publications concerning the chimpanzee link to human AIDS, and my hypothesis of vaccination initiation of HIV/AIDS following hepatitis B injections given gay men in New York City and Central African women between 1970 and 1974. My evidence from public records implicated the political nemesis of Robert F. Kennedy, Jr.’s father, President John F. Kennedy (JFK), Dr. Henry Kissinger.
Censored history is relevant here. “Tricky Dick” appointed Henry Kissinger as National Security Advisor under Vice President Nelson Rockefeller. Within a few weeks of Kissinger taking office in 1968, he ordered Admiral Zumwalt of the Navy to reassess America’s biological weapons capabilities, and from there Kissinger selected the option to develop the AIDS and Ebola-like viruses.
HIV (originally Simian Immunodeficiency Virus (SIV)) sprang from the chimpanzee (SIVcpz) and HepB vaccine. That plague virus found its way into the Merck & Co. HepB vaccine lots tested in Greenwich Village, Willowbrook State School for the mentally retarded, and Central Africa, according to scientific records.
Equally disturbing, not only was owner George W. Merck America’s leading biological weapons chief during and after World War II, but the Merck company received the lion’s share of the Nazi war chest to expand after the war into the world’s top vaccine producer.
[Editor’s Note: Henry Kissinger played an important role in the development of HIV/AIDS not only as a chief business advisor to Merck, but also as Nelson Rockefeller’s protege. Kissinger’s election to develop the AIDS-like bioweapons occurred in 1968. Two years later federal appropriations were granted to the project. The grant money poured into Kissinger’s counterpart in the Nixon White House–Roy Ash’s Litton Bionetics bioweapons firm. Copies of the 1972 Special Virus Cancer Program publication containing the major contracts and their summary reports evidencing the aforementioned assaults on human health and safety, is available through CureShoppe.com by clicking HERE.)
Independent HepB vaccine investigator and openly gay medical doctor, Alan Cantwell, compounded the evidence I advanced in 1996 with my publication of Emerging Viruses: AIDS & Ebola–Nature, Accident or Intentional? Cantwell published a series of books on behalf of the medical and gay communities, including Queer Blood.That book traced a large explosion of Gay Related Immune Dysfuction (“GRID” before it was called AIDS) to the 1978 HepB vaccine study of homosexuals in San Francisco and Denver.
Cantwell’s works, like mine, never received the attention this urgent intelligence was due. Years from now the same will be said for the excellent article published by Robert F. Kennedy, Jr. re-printed below.
Vaccine critics commonly confront the wrath of the “military-medical-media” or Big Pharma mafia complicit with Internet censorship by companies Google/YouTube and Wikipedia. Both of these propaganda mills are allied with leading biotechnology and pharmaceutical companies. This huge and powerful force squelches knowledge such as this work by Kennedy.
The world of social engineering through media persuasion, psychological operations, military neuroscience, psyops, psychotronics, and cyber-warfare is hard at work dulling the mass mind. This is the beast heavily implicated in the damage Kennedy writes about, and the damage control this work receives.
Especially obvious and obnoxious is the social media’s poisoning by mercenary trolls and scam-bots delivering disruptive, distracting, and disparaging messages. All of this is done to stifle public health and safety for multi-national corporate greed and profit. This beast suppresses unfairly and deceptively the natural medicine industry. The devil-doers preclude people from celebrating safe and effective substitutes for risky antibiotics and vaccines. These include OxySilver, the best vaccine substitute developed to date. OxySilver, and other innovations, is suppressed to profitably depopulate the planet as Bill Gates–the world’s leading vaccine propagandist and vaccine distributor–urges.
These topics and sad facts are absent from the World Mercury Project Team’s article. Perhaps they are perceived as too controversial to be raised by the perceived “liberal” Kennedy who relies here on two scientific studies in an attempt to reach intelligent decision-makers during this Age of Artificial Intelligence required to replace dumbed-down citizens.
If I had a magic wand, I would wave it over this article to immunize it and Kennedy against such trolls, scam bots, and censorship. And then I would pray that Kennedy’s organization and publications be freed from their psychosocial restraints to truth telling of the whole truth, nothing but the truth, to set humanity free from the vaccine genocide that largely relies on our collective criminal psychopathology called “evil obedience.”
The deadly and demonic CULTure in which we find ourselves being silenced, distressed, damaged and killed turns willfully-blind to the following article.
__________
By the World Mercury Project Team
In 1991, US public health authorities began recommending that all infants get the hepatitis B (HepB) vaccine, stipulating that they receive three doses within the first six months of life, starting at birth. The World Health Organization (WHO) followed suit with its own recommendation in 1992, instructing countries to vaccinate from birth even where hepatitis B virus was uncommon. Two 2018 studies (one in the US and one in India) take a closer look at the outcomes and implications of these blanket prescriptions. Although the studies focus on different aspects of their countries’ respective vaccine programs, both are cautionary tales, highlighting the fact that one-size-fits-all vaccine recommendations frequently steamroll over important biological risks and immune system subtleties, thereby introducing troublesome unintended consequences.
U.S. children and taxpayers on the hook
Until the early 2000s, the HepB vaccine in the US contained organic ethylmercury in the form of the preservative thimerosal—totaling 37.5 micrograms across the three doses. Regulators have never bothered to set any safety standards for ethylmercury, but government researchers have shown that the toxicity mechanisms of ethyl- and methylmercury (the type of mercury found in fish) are similar, and some believe that even the tiniest amounts carry a risk of adverse neuropsychological outcomes.
Fixated on the sole indicator of increasing HepB vaccine coverage, the Centers for Disease Control and Prevention (CDC) bragged in 2002 about having achieved a 90% national coverage rate in young children. However, a 2018 cross-sectional study published in the International Journal of Environmental Research and Public Health strongly suggests that the 1990s-era thimerosal-containing HepB vaccine had far less praiseworthy consequences, causing considerable harm to children and also exacting a high price from US taxpayers.
The researchers used National Health and Nutrition Examination Survey (NHANES) data to consider 1,192 boys aged 7-8 years—a sample statistically representative of over 24 million American boys. Building on their own and others’ prior research linking thimerosal to developmental disabilities, they considered boys who either did or did not receive three doses of thimerosal-containing (1994–2000) or thimerosal-reduced (2001–2007) HepB vaccine in infancy (the “exposure”), defining the outcome as increased long-term risk of receiving special education services. They restricted their sample to boys because of males’ greater susceptibility to mercury toxicity.
For the subgroup born between 1994 and 2000, boys who received three doses of thimerosal-containing HepB vaccine were at a more than nine-fold significantly higher risk of receiving special education services compared to boys receiving no doses of HepB vaccine. Extrapolating to the US population as a whole, this means that almost 1.3 million US boys born from 1994-2000 received special education services directly attributable to receiving three doses of thimerosal-containing HepB vaccine—costing taxpayers over $180 billion. An earlier study by some of the same authors found that in the decade from 1991–2001, exposure to thimerosal-containing HepB vaccines in the first six months of life resulted in an estimated 0.5–1 million US children being diagnosed with learning disabilities, representing lifetime costs in excess of $1 trillion.
Vaccine-induced versus natural immunity
As noted, the WHO has strongly promoted universal HepB vaccination and particularly the initial birth dose. However, in India, which introduced the HepB vaccine around 2006, approximately three-fifths (61%) of women deliver at home rather than in a health facility, making it next to impossible for health providers to administer newborn vaccines. In recognition of these realities, the Indian government’s two-pronged policy is to give HepB vaccine at birth to the 39% of babies born in institutional settings but to otherwise administer the first dose at six weeks. About 45% of Indian children receive the birth dose (although the WHO wants to double that number); irrespective of timing, 86% of Indian children reportedly receive all three HepB doses. However, India is home to an estimated one-third of the world’s unvaccinated children, meaning that many children still do not receive any HepB vaccine at all.
A 2018 study published in the Indian Journal of Pediatrics took advantage of these ready-made comparison groups. The multiregional study (2013–2015) recruited children 1-5 years of age who were already having blood drawn and whose parents consented to hepatitis B testing (N=2,671). Three-fifths (59%) of the children had received at least three doses of HepB vaccine, and just over half of these (880/1566) had their first dose at birth. The research team considered several intriguing questions:
- Are there any differences in vaccine efficacy for the two HepB schedules (birth dose versus six-week dose)? After testing all samples for a marker of chronic hepatitis B infection, the investigators concluded that birth vaccination offered “no added protection”—lending support to the government’s “pragmatic” approach of waiting until six weeks to vaccinate babies born at home.
- What are the levels of protective antibodies in fully HepB-vaccinated children, and do they change over time or according to birth dose? The researchers measured antibodies in a subset of 865 children who had received three doses of HepB vaccine. Seven in ten (70%) had protective levels of antibodies—but 30% of fully HepB-vaccinated children did not [emphasis added]. Moreover, when the researchers considered the children’s age, they found that vaccine-induced protection waned rapidly and significantly, falling from 82% of under-one-year-olds to 47% of five-year-olds. Receiving a birth dose made no difference.
- What are the levels of protective antibodies in children who have not received any HepB vaccine? Finally, the researchers examined hepatitis B immunity in 370 children who had never received any HepB vaccine. Nearly half (45%) of non-HepB-vaccinated one-year-olds were naturally immune, and 29% still had antibody protection at age 5. The researchers credited these protective levels of antibodies to natural, passively acquired immunity from unvaccinated mothers.
Overzealous promotion
The results of the two hepatitis B studies touch on many facets of the vaccine debate that the public health community is rarely, if ever, willing to discuss. These largely ignored topics include:
- The ongoing, adverse neurodevelopmental impact of toxic vaccine ingredients such as aluminum adjuvants and thimerosal, which is still present in annual flu shots, some meningococcal meningitis vaccines and the Td (tetanus-diphtheria) booster;
- The fact that economic and political factors—rather than vaccine effectiveness—are often key drivers of decisions about vaccine timing and schedules;
- The failure of HepB (and other) vaccines to reliably generate protective antibody levels in all fully vaccinated individuals—this phenomenon of impaired immunogenicity is a widely known “Achilles’ heel” of many vaccines; and
- The corresponding (and vastly underestimated) importance of natural immunity.
Regarding this latter point, the authors of the Indian HepB research, led by Dr. Jacob Puliyel, call attention to the “surprising” persistence of passively acquired hepatitis B antibodies in their own study population and in other studies. Pointing to studies of measles immunity, they note that mothers in highly measles-vaccinated communities have lower antibody levels and, therefore, far less ability to confer passive protection to their babies. This is because the measles vaccine “induces lower antibody levels than does natural infection and the antibody levels of vaccinated cohorts are no longer boosted by exposure to wild-type infection.” A study in the Czech Republic that compared 18-29-year-olds who were vaccinated and unvaccinated for mumps found that only 19% of vaccinated individuals in that age group had acquired immunity versus almost half (48%) of the unvaccinated, leading to the conclusion that only natural infection can lead to “long-term persistence of antibodies.” A growing number of studies also are indicating that prior exposure to natural infections such as measles and mumps may be health-protective later in life.
Back in 2003, Dr. Puliyel wrote a letter to the editor that questioned other researchers’ overestimation of the benefits of hepatitis B vaccination in terms of vaccine efficacy and cost per life-year saved. The letter concluded with a caution to guard against “overzealous” vaccine promotion. In the current climate of an ever-expanding vaccine schedule and hundreds more vaccines in the pipeline, those words of warning seem timelier than ever.